Telix H1 2026 Results: Investor Webcast Notification
Rhea-AI Summary
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) will release its financial results for the half-year ended June 30, 2026 on Thursday, August 20, 2026. An investor webcast and conference call are scheduled for 9:00 a.m. AEST that day (7:00 p.m. EDT on Wednesday, August 19, 2026). Participants can register via the provided online link.
According to Telix, the company is a commercial-stage global radiopharmaceutical business focused on targeted theranostics for cancer. Its portfolio includes prostate cancer imaging products Illuccix and Gozellix, and late-stage therapeutic candidates TLX591-Tx, TLX101-Tx and TLX250-Tx in pivotal trials.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | Clinical data publication | Positive | -5.5% | Phase 1 TLX591-Tx study publication reported favorable safety and indicative efficacy |
| Jul 20 | Q2 revenue update | Positive | +3.9% | Q2 revenue growth and FY 2026 revenue outlook exceeded US$1 billion |
| Jul 20 | Phase 3 trial initiation | Positive | +3.9% | First patient dosed in Phase 3 LUTEON trial for renal cancer |
| Jul 15 | Phase 2 trial initiation | Positive | -4.1% | First patients dosed in Phase 2 OPTIMAL-e prostate cancer study |
| Jul 01 | FDA trial alignment | Positive | +0.3% | FDA agreed Part 1 safety data supported advancing ProstACT Global Part 2 |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive announcements showed mixed alignment with subsequent 24-hour reactions.
Key Terms
theranostics medical
radiopharmaceutical medical
pivotal-stage trials medical
gallium-68 technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026.
An investor webcast and conference call will be held at 9:00 a.m. AEST on Thursday August 20, 2026 (7:00 p.m. EDT Wednesday August 19, 2026).
Participants can register for the webcast or teleconference at the following link:
https://s1.c-conf.com/diamondpass/10056417-pz2402.html
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.
Telix's commercial franchise is anchored by its prostate cancer imaging portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S. and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA). The Company's late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (131I-iodofalan) in recurrent glioblastoma, and TLX250-Tx (lutetium (177Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates.
Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.
| Investor Relations Annie Kasparian Annie.kasparian@telixpharma.com Charlene Jaw Charlene.jaw@telixpharma.com | Media Eliza Schleifstein Eliza@schleifsteinpr.com |
This announcement has been authorized for release by Telix Pharmaceuticals Limited’s Company Secretary, Shomalin Naidoo.
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
